Trial Profile
A Retrospective Observational Study Evaluating Major Bleeding (MB) And Potential Risk Factors In Patients With Venous Thromboembolism Treated With Rivaroxaban
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions
- 17 Feb 2017 New trial record